Figure 6.
Inhibition of CD13 with Bestatin, but not antibody neutralization, decreased myosin content in myotubes. (A) Western blot comparing myosin content in control vs. Bestatin-treated myotubes (mean ± SE, n = 7, *P < 0.05, t-test). (B) Western blot comparing myosin content in control myotubes vs. myotubes for which CD13 was neutralized in myotube culture medium or heat-inactivated CD23 antibody control (mean ± SE, n = 3, n.s., ANOVA).